Adding Immunotherapy and Targeted Therapy to Chemoradiotherapy for Non-small Cell Lung Cancer

For several decades, the standard non-surgical treatment approach for patients with locally advanced non-small cell lung cancer was definitive thoracic radiotherapy with concurrent cytotoxic chemotherapy. Based on recent positive randomized trials, most patients should now be treated with adjuvant immunotherapy or targeted therapy. Future studies should establish novel biomarker-driven adjuvant therapy options, address the optimal sequencing of local and systemic treatments, and define how thoracic radiotherapy should be modified in this era of adjuvant therapy.